Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

3.900 -0.350 (-8.24%)
Streaming Delayed Price Updated: 11:32 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 250 stocks hit new 52-week lows. 
Via Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan 
Via Benzinga
SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd. 
Via Benzinga
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment 
Via Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel... 
Via Benzinga
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment 
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins
JV Targets Potential Drugs for Cancers and Infectious Diseases 
Via Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. 
Via Benzinga
Why Are Psychedelics Stocks Up Today?
Shares of SEEL stock are in the green after the company received a grant from the Michael J. Fox Foundation to advance its SLS-004 candidate. 
Via InvestorPlace
S&P 500 Edges Higher; Nordstrom Shares Plummet
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday. 
Via Benzinga
Dow Rises Over 100 Points; US Crude Oil Inventories Decline Higher Than Expected
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Why SciSparc Stock Is Skyrocketing Today
SciSparc Ltd (NASDAQ: SPRC) shares are soaring Wednesday after the company announced additional pre-clinical results of its psychedelic-based pharma collaboration for treatment of cocaine addiction... 
Via Benzinga
Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! 
Via InvestorPlace
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket
Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share. 
Via Benzinga
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 31 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 39 companies reached new 52-week lows. 
Via Benzinga
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of... 
Via Benzinga
SciSparc Announces Buyback Equal To 12% Of Float
SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par... 
Via Benzinga
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study... 
Via Benzinga
SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed... 
Via Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain. 
Via Benzinga
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
SciSparc Ltd. 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.